CN113473965A - 通过纳米乳化配制的大麻油粉末、其产生方法和用途 - Google Patents

通过纳米乳化配制的大麻油粉末、其产生方法和用途 Download PDF

Info

Publication number
CN113473965A
CN113473965A CN201980067584.5A CN201980067584A CN113473965A CN 113473965 A CN113473965 A CN 113473965A CN 201980067584 A CN201980067584 A CN 201980067584A CN 113473965 A CN113473965 A CN 113473965A
Authority
CN
China
Prior art keywords
powder
cannabinoid
maltodextrin
pluronic
cannabis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067584.5A
Other languages
English (en)
Chinese (zh)
Inventor
沙洛莫·马格达希
利拉斯·拉鲁什
拉斐尔·埃兹拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanak Technology Co ltd
Original Assignee
Kanak Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanak Technology Co ltd filed Critical Kanak Technology Co ltd
Publication of CN113473965A publication Critical patent/CN113473965A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980067584.5A 2018-08-13 2019-03-11 通过纳米乳化配制的大麻油粉末、其产生方法和用途 Pending CN113473965A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
IL261132 2018-08-13
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (1)

Publication Number Publication Date
CN113473965A true CN113473965A (zh) 2021-10-01

Family

ID=63998426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067584.5A Pending CN113473965A (zh) 2018-08-13 2019-03-11 通过纳米乳化配制的大麻油粉末、其产生方法和用途

Country Status (9)

Country Link
US (2) US11712430B2 (https=)
EP (1) EP3716946A1 (https=)
JP (1) JP2021535935A (https=)
CN (1) CN113473965A (https=)
AU (1) AU2019322212B2 (https=)
BR (1) BR112021009869A2 (https=)
CO (1) CO2021007647A2 (https=)
IL (2) IL261132A (https=)
WO (1) WO2020035850A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020220141A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
AU2020330527A1 (en) * 2019-08-12 2022-02-24 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
CA3166084C (en) 2020-07-29 2025-06-10 Karnak Technologies, Llc Oral compositions of beneficial lipophilic, nutriceutical, and edible oil food supplements
AU2021317264A1 (en) * 2020-07-29 2022-09-22 Karnak Technologies, Llc Improved formulations of lipophilic subtances for cosmetic uses
US20230270678A1 (en) * 2020-07-29 2023-08-31 Karnak Technologies, Llc Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
EP4196112A4 (en) * 2020-08-14 2024-10-16 Capheads LLC CANNABIS-DERIVED RESIN DOSING CAPSULE AND METHOD FOR THE PRODUCTION THEREOF
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
US20240415854A1 (en) 2023-06-16 2024-12-19 Miles J. Terry Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
WO2026037496A1 (en) * 2024-08-14 2026-02-19 Tetra Pharm Technologies A self-emulsifying solid composition comprising a cannabinoid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052119A1 (en) * 2010-08-24 2012-03-01 Trevor Percival Castor Nanoencapsulated delta-9-tetrahydrocannabinol
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
WO2017072762A1 (en) * 2015-10-26 2017-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Novel cannabinoid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2804587T3 (da) 2012-01-19 2019-08-12 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
US10213391B2 (en) 2014-05-06 2019-02-26 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
AU2016231788A1 (en) 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
EP3442522A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. METHOD FOR PRODUCING HYDROPHILIZED CANNABI OIL USING EMULSIFIERS AND RELATED CANNABINOID COMPOSITIONS
EP3558297A1 (en) * 2016-12-20 2019-10-30 Tilray, Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
US20120052119A1 (en) * 2010-08-24 2012-03-01 Trevor Percival Castor Nanoencapsulated delta-9-tetrahydrocannabinol
WO2017072762A1 (en) * 2015-10-26 2017-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Novel cannabinoid formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DURAN-LOBATOMATILDEETAL: "Comparative studyofchitosan-andPEG-coatedlipid andPLGAnanoparticlesasoraldelivery systemsforcannabinoids", JOURNALOFNANOPARTICLERESEARCH, KLUWER ACADEMICPUBLISHERS, DORDRECHT, NL, vol. 17, pages 3 - 4 *
MARTÍN-BANDERAS L, ET AL.: "Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms", 《 COLLOIDS AND SURFACES B: BIOINTERFACES》, vol. 123, pages 2 *
MARTÍN-BANDERAS L, ET AL.: "MartEngineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms", 《 COLLOIDS AND SURFACES B: BIOINTERFACES》, vol. 123, 16 September 2014 (2014-09-16), pages 2 *

Also Published As

Publication number Publication date
US20210059975A1 (en) 2021-03-04
CA3086887A1 (en) 2020-02-20
AU2019322212B2 (en) 2022-09-29
WO2020035850A1 (en) 2020-02-20
IL275430A (en) 2020-08-31
EP3716946A1 (en) 2020-10-07
IL261132A (en) 2018-11-04
US20230321031A1 (en) 2023-10-12
JP2021535935A (ja) 2021-12-23
CO2021007647A2 (es) 2021-08-30
US11712430B2 (en) 2023-08-01
AU2019322212A1 (en) 2021-04-08
BR112021009869A2 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
CN113473965A (zh) 通过纳米乳化配制的大麻油粉末、其产生方法和用途
CA2981772C (en) Oral solid cannabinoid formulations, methods for producing and using thereof
US9925149B2 (en) Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
US20210299081A1 (en) Solid cannabinoid formulation for oral administration
Ferreira et al. Ketoprofen-loaded pomegranate seed oil nanoemulsion stabilized by pullulan: selective antiglioma formulation for intravenous administration
CN116322732A (zh) 用治疗剂补充产品的组合物及其使用方法
CN113226293B (zh) 利用壳聚糖涂覆的纳米胶囊及其用途
Lai et al. Nanocrystals as effective delivery systems of poorly water-soluble natural molecules
WO2017098502A1 (en) Compositions of therapeutic substances, methods and uses thereof
WO2020146478A1 (en) Cannabinoid formulations for treating alcohol hangover
US20260069608A1 (en) Methods of Delivering Alcohol-Soluble Species Including DHEA, Pregnenolone, and Chrysin for Reducing Menopausal Symptoms with Microemulsion Delivery Systems
Falcão et al. Nanotechnology in phytotherapy: Current challenges of lipid-based nanocarriers for the delivery of natural products
AU2021317263B2 (en) Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
Alshawwa et al. Solid lipid Lyo-Nanosuspension: a promising stabilized oral delivery system for the antihyperglycemic extract of mistletoe Plicosepalus acacia
JP2020121974A (ja) 天然材料の粒子および抽出物を含むナノ懸濁液
CN118695854A (zh) 食品相关颗粒、生产方法及生产装置
HK40053715A (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
US20220193008A1 (en) Bioaccessibile compositions of lipophilic compounds and process thereof
CA3086887C (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
RU2765946C1 (ru) Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления
SI26054A (sl) Supernasičljiv brez olja samo-nanoemulgirni sistem za dovajanje zdravil - SNEDDS za v vodi slabo topne farmacevtske sestavine in postopek njegove priprave
HK40094216A (zh) 用治疗剂补充产品的组合物及其使用方法
Boraie Nebulized solid lipid nanoparticles for the potential

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053715

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211001

WD01 Invention patent application deemed withdrawn after publication